A 28-year-old woman with newly diagnosed sputum-positive pulmonary TB is registered under RNTCP. She is on standard first-line therapy (HRZE for 2 months followed by HR for 4 months). She reports irregular attendance at the TB clinic and admits to missing doses occasionally. At the 3-month follow-up visit, her sputum smear microscopy shows 2+ AFB positivity. What is the most critical intervention to prevent treatment failure and drug resistance in this patient?

Explanation

## Adherence and DOT in RNTCP Management **Key Point:** Directly observed therapy (DOT) is the cornerstone of RNTCP to ensure treatment adherence and prevent treatment failure and drug resistance. ### The Role of DOT in RNTCP DOT is defined as: - Observation of the patient ingesting each dose of anti-TB drugs - Performed by a trained health worker (ASHA, ANM, or TB health visitor) - Mandatory for all TB patients under RNTCP **High-Yield:** Non-adherence is the PRIMARY cause of treatment failure and development of drug resistance in TB. DOT addresses this directly and is more cost-effective than hospitalization. ### Why DOT is Superior to Other Interventions | Intervention | Rationale | Evidence | |---|---|---| | **DOT + Adherence Counseling** | Directly addresses the root cause (poor adherence); prevents resistance development | Cure rates >95% with DOT | | Dose escalation | Does not address adherence; increases toxicity without benefit | Not recommended by NTEP | | Hospitalization | Expensive, resource-intensive; not feasible at scale; addresses symptom management only | Reserved for complications, not routine failure | | Premature switch to 2nd-line | Inappropriate without DST; wastes expensive drugs; increases toxicity | Only after DST confirms resistance | ### RNTCP Protocol for Adherence Issues ```mermaid flowchart TD A[Patient with poor adherence/persistent positivity]:::outcome A --> B[Assess adherence & investigate barriers]:::action B --> C[Implement DOT with ASHA/ANM]:::action C --> D[Enhanced counseling on TB & treatment]:::action D --> E{Response at 3-4 weeks?}:::decision E -->|Yes| F[Continue DOT till completion]:::action E -->|No| G[Perform DST & investigate resistance]:::action G --> H{MDR-TB confirmed?}:::decision H -->|Yes| I[Initiate second-line therapy]:::action H -->|No| J[Reassess adherence & compliance]:::action ``` **Clinical Pearl:** In this case, the patient is only at 3 months of a 6-month regimen. Sputum positivity at this stage with documented poor adherence strongly suggests inadequate drug exposure, NOT drug resistance. DOT will likely resolve the issue. **Mnemonic: DOT-RNTCP** — **D**irectly **O**bserved **T**herapy is the **R**oot solution for **N**on-adherence in **T**B **C**ontrol **P**rograms. [cite:NTEP Guidelines 2023, Park 26e Ch 5]